Maze Therapeutics News and Activities

Maze Therapeutics is one of the...

• Russell 3000;
• TOB Iconic 10,000.

Maze Therapeutics is a company listed under the stock ticker MAZE (US).

Acquisition, funding and merger involving Maze Therapeutics.

• Maze Therapeutics has filed its IPO. Its stock ticker will be MAZE. (posted on February 4 2025).

View the org chart displaying its 25 main executives

Most searched biographies at Maze Therapeutics

• Jason Coloma, Director, President and Chief Executive Officer
• Daniel Spiegelman, Director
• Catherine Sohn, Director

Popular executive movements at Maze Therapeutics

• Misbah Tahir who is Chief Financial Officer, will become Chief Financial Officer and Principal Accounting Officer on Jun. 1, 2026  (posted on May 25 2026).
• Amy Bachrodt, Senior Vice President, Finance, will leave the company on Jun. 1, 2026  (posted on May 25 2026).
• Herve Hoppenot has joined the company as Chairman of the Board  (posted on October 6 2025).

Create your alert
to follow the executive moves at Maze Therapeutics.

Maze Therapeutics has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Maze Therapeutics

• News & Press | Maze Therapeutics

Social media about Maze Therapeutics

• Maze Therapeutics on Wikipedia, Google News & Yahoo Finance
• Maze Therapeutics on LinkedIn, X (Twitter) & YouTube